RU2019132222A - Ингибиторы ezh2 человека и способы их применения - Google Patents
Ингибиторы ezh2 человека и способы их применения Download PDFInfo
- Publication number
- RU2019132222A RU2019132222A RU2019132222A RU2019132222A RU2019132222A RU 2019132222 A RU2019132222 A RU 2019132222A RU 2019132222 A RU2019132222 A RU 2019132222A RU 2019132222 A RU2019132222 A RU 2019132222A RU 2019132222 A RU2019132222 A RU 2019132222A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- acid position
- sequence represented
- wild
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 18
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title claims 12
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title claims 12
- 239000003112 inhibitor Substances 0.000 title claims 6
- 235000001014 amino acid Nutrition 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 22
- 238000006467 substitution reaction Methods 0.000 claims 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 239000004475 Arginine Substances 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000006994 Precancerous Conditions Diseases 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 4
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 150000003680 valines Chemical class 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
Claims (19)
1. Способ лечения или облегчения симптома рака или предракового состояния у индивида, включающий введение индивиду, экспрессирующему мутантную EZH2, содержащую мутацию в домене субстратного кармана, как определено в последовательности, представленной SEQ ID NO: 6, терапевтически эффективного количества ингибитора EZH2.
2. Способ по п. 1, где мутантная EZH2 представляет собой полипептид мутантной EZH2 или последовательность нуклеиновой кислоты, кодирующую полипептид мутантной EZH2.
3. Способ по п. 1, где рак представляет собой лимфому, лейкоз или меланому.
4. Способ по п. 3, где лимфома выбрана из группы, состоящей из неходжкинской лимфомы, фолликулярной лимфомы и диффузной крупноклеточной B-клеточной лимфомы.
5. Способ по п. 3, где лейкоз представляет собой хронический миелогенный лейкоз (CML).
6. Способ по п. 1, где предраковое состояние представляет собой синдромы миелодисплазии (MDS, ранее известной как предлейкозный синдром).
7. Способ по п. 1, где мутантная EZH2 содержит мутацию в аминокислотном положении 677, 687, 674, 685 или 641 последовательности, представленной SEQ ID NO: 1.
8. Способ по п. 7, где указанная мутация выбрана из группы, состоящей из замещения глицином (G) остатка дикого типа аланина (A) в аминокислотном положении 677 последовательности, представленной SEQ ID NO: 1 (A677G); замещения валином (V) остатка дикого типа аланина (A) в аминокислотном положении 687 последовательности, представленной SEQ ID NO: 1 (A687V); замещения метионином (M) остатка дикого типа валина (V) в аминокислотном положении 674 последовательности, представленной SEQ ID NO: 1 (V674M); замещения гистидином (H) остатка аргинина (R) дикого типа в аминокислотном положении 685 последовательности, представленной SEQ ID NO: 1 (R685H); замещения цистеином (C) остатка аргинина (R) дикого типа в аминокислотном положении 685 последовательности, представленной SEQ ID NO: 1 (R685C); замещения фенилаланином (F) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641F); замещения гистидином (H) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641H); замещения аспарагином (N) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641N); замещения серином (S) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641S); и замещения цистеином (C) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641C).
9. Способ по п. 1, где ингибитор EZH2 выбран из соединений, перечисленных в таблице 1.
10. Способ определения способности к ответу на лечение ингибитором EZH2 у индивида, имеющего рак или предраковое состояние, включающий
a) получение образца у индивида; и
b) выявление мутации EZH2 в домене субстратного кармана, как определено в последовательности, представленной SEQ ID NO: 6, где присутствие указанной мутации указывает на то, что индивид отвечает на лечение ингибитором EZH2.
11. Способ по п. 10, где рак представляет собой лимфому, лейкоз или меланому.
12. Способ по п. 11, где лимфома выбрана из группы, состоящей из неходжкинской лимфомы, фолликулярной лимфомы и диффузной крупноклеточной B-клеточной лимфомы.
13. Способ по п. 11, где лейкоз представляет собой хронический миелогенный лейкоз (CML).
14. Способ по п. 10, где предраковое состояние представляет собой синдромы миелодисплазии (MDS, ранее известной как предлейкозный синдром).
15. Способ по п. 10, где мутация представляет собой мутацию замещения в аминокислотном положении 677, 687, 674, 685 или 641 последовательности, представленной SEQ ID NO: 1.
16. Способ по п. 15, где указанная мутация выбрана из группы, состоящей из замещения глицином (G) остатка дикого типа аланина (A) в аминокислотном положении 677 последовательности, представленной SEQ ID NO: 1 (A677G); замещения валином (V) остатка дикого типа аланина (A) в аминокислотном положении 687 последовательности, представленной SEQ ID NO: 1 (A687V); замещения метионином (M) остатка дикого типа валина (V) в аминокислотном положении 674 последовательности, представленной SEQ ID NO: 1 (V674M); замещения гистидином (H) остатка аргинина (R) дикого типа в аминокислотном положении 685 последовательности, представленной SEQ ID NO: 1 (R685H); замещения цистеином (C) остатка аргинина (R) дикого типа в аминокислотном положении 685 последовательности, представленной SEQ ID NO: 1 (R685C); замещения фенилаланином (F) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641F); замещения гистидином (H) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641H); замещения аспарагином (N) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641N); замещения серином (S) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641S); и замещения цистеином (C) остатка дикого типа тирозина (Y) в аминокислотном положении 641 последовательности, представленной SEQ ID NO: 1 (Y641C).
17. Способ по п. 10, где ингибитор EZH2 выбран из соединений, перечисленных в таблице 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/418,242 US9175331B2 (en) | 2010-09-10 | 2012-03-12 | Inhibitors of human EZH2, and methods of use thereof |
US13/418,242 | 2012-03-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014141045A Division RU2704445C2 (ru) | 2012-03-12 | 2013-03-12 | Ингибиторы ezh2 человека и способы их применения |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2019132222A true RU2019132222A (ru) | 2021-06-03 |
Family
ID=47913638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019132222A RU2019132222A (ru) | 2012-03-12 | 2013-03-12 | Ингибиторы ezh2 человека и способы их применения |
RU2014141045A RU2704445C2 (ru) | 2012-03-12 | 2013-03-12 | Ингибиторы ezh2 человека и способы их применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014141045A RU2704445C2 (ru) | 2012-03-12 | 2013-03-12 | Ингибиторы ezh2 человека и способы их применения |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP3536314A1 (ru) |
JP (2) | JP6321619B2 (ru) |
KR (4) | KR102587175B1 (ru) |
CN (2) | CN104540500B (ru) |
AU (4) | AU2013232229B2 (ru) |
CA (2) | CA3177515A1 (ru) |
DK (1) | DK2825161T3 (ru) |
ES (1) | ES2718900T3 (ru) |
HK (1) | HK1205938A1 (ru) |
HU (1) | HUE042271T2 (ru) |
PL (1) | PL2825161T3 (ru) |
PT (1) | PT2825161T (ru) |
RU (2) | RU2019132222A (ru) |
TR (1) | TR201904660T4 (ru) |
WO (1) | WO2013138361A1 (ru) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013155464A1 (en) * | 2012-04-13 | 2013-10-17 | Epizyme, Inc. | Combination therapy for treating cancer |
RU2658911C2 (ru) | 2012-04-13 | 2018-06-26 | Эпизайм, Инк. | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека |
EP2900653A1 (en) * | 2012-09-28 | 2015-08-05 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
NZ746054A (en) | 2012-10-15 | 2020-07-31 | Epizyme Inc | Methods of treating cancer |
US10092572B2 (en) | 2012-10-15 | 2018-10-09 | Epizyme, Inc. | Substituted benzene compounds |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
EA038869B1 (ru) | 2013-10-16 | 2021-10-29 | Эпизим, Инк. | Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения |
JP2016533364A (ja) * | 2013-10-18 | 2016-10-27 | エピザイム,インコーポレイティド | 癌を処置する方法 |
CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
EP3111222A1 (en) * | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
SG10201811128RA (en) * | 2014-06-17 | 2019-01-30 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
CA2952285A1 (en) | 2014-06-19 | 2015-12-23 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
JP2017532338A (ja) | 2014-10-16 | 2017-11-02 | エピザイム,インコーポレイティド | 癌を治療する方法 |
EP3214935A4 (en) | 2014-11-06 | 2018-08-29 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
ES2947819T3 (es) * | 2014-11-17 | 2023-08-21 | Epizyme Inc | Método para el tratamiento del cáncer con N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-carboxamida |
SG11201703880VA (en) | 2014-12-23 | 2017-07-28 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
WO2016172332A1 (en) * | 2015-04-22 | 2016-10-27 | The University Of North Carolina At Chapel Hill | A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility |
JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム,インコーポレイティド | リンパ腫を処置するためのezh2阻害剤 |
KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
US20180296563A1 (en) * | 2015-09-25 | 2018-10-18 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor |
EP3371601A1 (en) * | 2015-11-05 | 2018-09-12 | Epizyme Inc | Flow cytometry for monitoring histone h3 methylation status |
AU2017252460B2 (en) * | 2016-04-22 | 2021-11-18 | Dana-Farber Cancer Institute, Inc. | EZH2 inhibitors and uses thereof |
US10933068B2 (en) * | 2016-05-26 | 2021-03-02 | Sonic Master Limited | Modulators of DUX4 for regulation of muscle function |
JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤の使用 |
EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
IL263429B (en) | 2016-06-20 | 2022-08-01 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
EP3532605A4 (en) | 2016-10-26 | 2021-01-13 | Sonic Master Limited | ENHANCED GENERATION OF MUSCLE LINE CELLS AND THEIR THERAPEUTIC USES |
EP3441388A1 (en) | 2016-11-11 | 2019-02-13 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 4,5,6-tri-substituted indazoles derivatives, preparation thereof, and use thereof in medicines |
CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2019204998A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京肿瘤医院 | Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用 |
JP7411256B2 (ja) * | 2018-07-27 | 2024-01-11 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 多置換ベンゼン環化合物、製造方法及びその用途 |
JP2022529523A (ja) | 2019-04-22 | 2022-06-22 | ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 小児対象において神経膠腫を治療するためのtg02の使用 |
CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
CN113024516B (zh) * | 2021-03-29 | 2022-05-17 | 中国药科大学 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
WO2023025856A1 (en) | 2021-08-25 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
JP5160885B2 (ja) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法 |
ES2324435B1 (es) * | 2005-10-27 | 2010-05-31 | Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
WO2008101118A2 (en) * | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
SI2566327T1 (sl) | 2010-05-07 | 2017-07-31 | Glaxosmithkline Llc | Indoli |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
KR102373074B1 (ko) * | 2010-09-10 | 2022-03-11 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
US9730925B2 (en) * | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
-
2013
- 2013-03-12 KR KR1020227034498A patent/KR102587175B1/ko active IP Right Grant
- 2013-03-12 PT PT13711265T patent/PT2825161T/pt unknown
- 2013-03-12 TR TR2019/04660T patent/TR201904660T4/tr unknown
- 2013-03-12 ES ES13711265T patent/ES2718900T3/es active Active
- 2013-03-12 EP EP18214827.0A patent/EP3536314A1/en active Pending
- 2013-03-12 JP JP2015500523A patent/JP6321619B2/ja active Active
- 2013-03-12 KR KR1020237033924A patent/KR20230145531A/ko not_active Application Discontinuation
- 2013-03-12 PL PL13711265T patent/PL2825161T3/pl unknown
- 2013-03-12 KR KR1020147028560A patent/KR102267502B1/ko active IP Right Grant
- 2013-03-12 AU AU2013232229A patent/AU2013232229B2/en active Active
- 2013-03-12 CN CN201380024734.7A patent/CN104540500B/zh active Active
- 2013-03-12 CN CN201910052279.0A patent/CN110420327B/zh active Active
- 2013-03-12 EP EP13711265.2A patent/EP2825161B1/en active Active
- 2013-03-12 DK DK13711265.2T patent/DK2825161T3/en active
- 2013-03-12 KR KR1020217018417A patent/KR102453519B1/ko active IP Right Grant
- 2013-03-12 WO PCT/US2013/030565 patent/WO2013138361A1/en active Application Filing
- 2013-03-12 CA CA3177515A patent/CA3177515A1/en active Pending
- 2013-03-12 RU RU2019132222A patent/RU2019132222A/ru unknown
- 2013-03-12 RU RU2014141045A patent/RU2704445C2/ru active
- 2013-03-12 CA CA2867282A patent/CA2867282C/en active Active
- 2013-03-12 HU HUE13711265A patent/HUE042271T2/hu unknown
-
2015
- 2015-07-08 HK HK15106526.3A patent/HK1205938A1/xx unknown
-
2017
- 2017-12-22 JP JP2017245743A patent/JP6592071B2/ja active Active
-
2018
- 2018-02-19 AU AU2018201176A patent/AU2018201176A1/en not_active Abandoned
-
2019
- 2019-10-17 AU AU2019250181A patent/AU2019250181A1/en not_active Abandoned
-
2021
- 2021-04-07 AU AU2021202119A patent/AU2021202119A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019132222A (ru) | Ингибиторы ezh2 человека и способы их применения | |
JP2018083821A5 (ru) | ||
JP2015511603A5 (ru) | ||
RU2018145311A (ru) | Способы лечения рака | |
RU2014138499A (ru) | АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FycRIIB | |
RU2019134551A (ru) | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы | |
RU2014106994A (ru) | СПОСОБ ОБНАРУЖЕНИЯ ТРАНСФОРМАНТА СОИ рDAB9582.814.19.1 | |
CY1121519T1 (el) | Καθαρισμος της υδουρονικης-2-σουλφατασης | |
EA201200898A1 (ru) | Специфичный сорбент для связывания белков и пептидов и способ разделения с его использованием | |
NZ710434A (en) | Tfpi inhibitors and methods of use | |
EA201590162A1 (ru) | МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ | |
RU2015125575A (ru) | Композиции и способы для лечения злокачественной опухоли | |
BR112012021337A2 (pt) | formulações de apixaban. | |
TR201909189T4 (tr) | C-kit ki̇naz i̇nhi̇bi̇törü bi̇leşi̇kler ve bi̇leşi̇mler | |
RU2017105486A (ru) | Фармацевтическая композиция для лечения злокачественной опухоли, положительной по мутации flt3, ингибитор мутантного flt3 и их применение | |
EA201390740A1 (ru) | Способ лечения с использованием ингибитора braf | |
WO2015172085A3 (en) | Biomarkers for response to pi3k inhibitors | |
MX2014006399A (es) | Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. | |
EA201070521A1 (ru) | Способы идентификации, очистки и обогащения незрелых или стволовых клеток-инициаторов злокачественного роста из опухолей и их применение | |
EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
JP2009537798A5 (ru) | ||
MX2016017115A (es) | Metodos y reactivos para la purificacion de proteinas. | |
EA201790538A2 (ru) | Белок cd24 для подавления повреждения ткани, опосредованного damp | |
RU2016104651A (ru) | Устойчивые к протеазам пептидные лиганды | |
WO2008142664A3 (en) | Exposed thymidine kinase 1 peptides, ligands and methods employing the same |